A superagonist variant of peptide MART1/melan A27-35 elicits anti- melanoma CD8+ T cells with enhanced functional characteristics: Implication for more effective immunotherapy

Cancer Research

Volumn 59, Issue 2, 1999, Pages 301-306

  Rivoltini, Licia ^a   Squarcina, Paola ^a   Loftus, Douglas J ^b   Castelli, Chiara ^a   Tarsini, Paolo ^a   Mazzocchi, Arabella ^a   Rini, Francesca ^a   Viggiano, Vincenzo ^a   Belli, Filiberto ^a   Parmiani, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSTIMULATING AGENT; PEPTIDE DERIVATIVE;

ARTICLE; CANCER IMMUNOTHERAPY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL CULTURE;

CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; HLA-A2 ANTIGEN; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-2; MELANOMA; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA;

EID: 0033555613     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Rosenberg, S. A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today, 18: 175-182, 1997.
2. Boon, T., Coulie, P. G., and Van den Eynde, B. Tumor antigens recognized by T cells. Immunol. Today, 18: 267-268, 1997.
3. Rivoltini, L., Loftus, D. J., Squarcina, P., Castelli, C. Rini, F., Arienti, F., Belli, F., Marincola, F. M., Geisler, C., Borsatti, A., Appella, E., and Parmiani, G. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T cell reactivity. Crit. Rev. Immunol., 18: 55-64, 1998.
4. Rogers, P. R., Grey, H. M., and Croft, M. Modulation of naive CD4 T cell activation with altered peptide ligands: the nature of the peptide and presentation in the context of costimulation are critical for a sustained response. J. Immunol., 160: 3698-3704, 1998.
5. Dressel, A., Chin, J. L., Sette, A., Gausling, R., Hollsberg, P., and Hafler, D. A Autoantigen recognition by human CD8 T cell clones: enhanced agonist response induced by altered peptide ligands. J. Immunol., 159: 4943-4951, 1997.
6. Vergelli, M., Hemmer, B., Kalbus, M., Vogt, A. B., Ling, N., Conlon, P., Coligan, J. E., McFarland, H., and Martin, R. Modifications of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands for autoreactive T cells. J. Immunol., 158: 3746-3752, 1997.
7. Nicholson, L. B., Waldner, H., Carrizosa, A. M., Sette, A., Collins, M., and Kuchroo, V. K. Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: implications for autoimmunity. Proc. Natl. Acad. Sci. USA, 95: 264-269, 1998.
8. Kersh, G. J., and Allen, P. M. Essential flexibility in the T-cell recognition of antigen. Nature (Lond.), 380: 495-498, 1996.
9. Höllsberg, P., Weber, B., Dangond, F., Batra, V., Sette, A., and Hafler, D. Differential activation of proliferation and cytotoxicity in human T-cell lymphotropic virus type I Tax-specific CD8 T cells by altered peptide ligand. Proc. Natl. Acad. Sci. USA, 92: 4036-4044, 1995.
10. 27-35. Cancer Res., 58: 2433-2439, 1998.
11. Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood,. S., Sette, A., Robbins, P. F., Marincola, F. M., Salgaller, M. L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART1. J. Immunol., 154: 2257-2265, 1995.
12. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Identification of the immunodominant peptides of MART1 human melanoma antigen recognized by the majority of the HLA-A2 restricted tumor-infiltrating lymphocytes. J. Exp. Med., 180: 347-352, 1994.
13. 27-35. J. Exp. Med., 184: 647-657, 1996.
14. Genevee, C., Diu, A., Nierat, J., Caignard, A., Dietrich, P., Ferradini, L., Roman-Roman, S., Triebel, F., and Hercend, T. An experimentally validated panel of subfamily specific oligonucleotide primers (Val-w29/Vb1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur. J. Immunol., 22: 1261-1269, 1992.
15. Dutton, R. W. The regulation of the development of CD8 effector T cells. J. Immunol., 157: 4287-4292, 1996.
16. + TC1 cells: loss of IL-2 synthesis and autonomous proliferation but retention of cytotoxicity and synthesis of other cytokines. J. Exp. Med., 182: 1505-1515, 1995.
17. Madrenas, J., Schwartz, R. H., and Germain, R. N. Interleukin 2 production, not the pattern of early T-cell antigen receptor-dependent tyrosine phosphorylation, controls anergy induction by both agonists and partial agonists. Proc. Natl. Acad. Sci. USA, 93: 9736-9741, 1996.
18. Gervois, N., Guilloux, Y., Diez, E., and Jotereau, F. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J. Exp. Med., 183: 2403-2407, 1996.
19. Cormier, J. N., Salgaller, M. L., Prevette, T., Barracchini, K. C., Rivoltini, L., Restifo, N. P., Rosenberg, S. A., and Marincola, F. M. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART1/Melan A. Cancer J. Sci. Am., 3: 37-44, 1997.
20. Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W. M., Melief, C. J., Oseroff, C., Yuan, L., Ruppert, J., Sidney, J., del Guercio, M., Southwood, S., Kubo, R., Chestnut, R., Grey, H., and Chisari, F. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol., 153: 5586-5592, 1994.
21. Parkhurst, M. R., Salgaller, M. L., Southwood, S., Robbins, P. F., Sette, A., Rosenberg, S. A., and Kawakami, Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol., 157: 2539-2548, 1996.
22. Valmori, D., Fonteneau, J. F., Lizana, C. M., Gervois, N., Lienard, D., Rimoldi, D., Jongeneel, V., Jotereau, F., Cerottini, J. C., and Romero, P. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART1 immunodominant peptide analogues. J. Immunol., 160: 1750-1758, 1998.
23. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H. and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.
24. Bronte, V., Tsung, K., Rao, J. B., Chen, P. W., Wang, M., Rosenberg, S. A., and Restifo. N. P. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol., 154: 5282-5292, 1995.